Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP
It lost about ¥359 for every ¥100 of sales at the operating level. Revenue changed +324.3% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | 20.2% | 0.27× | 5.4% | 1.39× | 7.5% |
| 2022 | — | —× | -12.7% | —× | — |
| 2023 | — | —× | -13.0% | —× | — |
| 2024 | — | —× | -22.6% | —× | — |
| 2025 | — | —× | -19.6% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 708 | 374 | 61 | 54 | 231 |
| Cost of revenue | 138 | 133 | 23 | 38 | 117 |
| Gross profit | 571 | 241 | 38 | 17 | 114 |
| SG&A | 500 | 667 | 735 | 913 | 942 |
| Operating income | 71 | -425 | -697 | -896 | -828 |
| Pretax income | 145 | -472 | -586 | -870 | -761 |
| Income tax | 2 | 2 | 3 | 2 | 3 |
| Net income attributable to owners | 143 | -474 | -589 | -872 | -764 |
| Operating margin | 10.0% | -113.5% | -1141.2% | -1645.9% | -358.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥1.61B | ¥3.44B | ¥2.87B | ¥2.05B | ¥2.38B |
| Total assets | ¥2.65B | ¥4.82B | ¥4.21B | ¥3.52B | ¥4.27B |
| Net assets | ¥1.9B | ¥3.77B | ¥3.2B | ¥2.54B | ¥2.76B |
| Share capital | ¥100M | ¥1.27B | ¥1.28B | ¥1.36B | ¥1.83B |
| Property, plant and equipment | ¥27.3M | ¥189M | ¥170M | ¥141.8M | ¥155.1M |
| Intangible assets excluding goodwill | ¥4.8M | ¥5.5M | ¥4.4M | ¥4.2M | ¥3.4M |
| Current assets | ¥2.56B | ¥4.57B | ¥3.99B | ¥3.24B | ¥3.93B |
| Current liabilities | ¥386.3M | ¥682.5M | ¥666.3M | ¥648.6M | ¥866.1M |
| Short-term borrowings | ¥128.8M | ¥467.3M | ¥550M | ¥507.8M | ¥485M |
| Long-term borrowings | ¥359.8M | ¥363M | ¥345M | ¥327M | ¥642.3M |
| Total liabilities | ¥746.1M | ¥1.05B | ¥1.01B | ¥975.6M | ¥1.51B |
| Equity attributable to owners of parent | ¥1.9B | ¥3.77B | ¥3.2B | ¥2.49B | ¥2.66B |
| Retained earnings | -¥922.9M | -¥1.4B | -¥1.99B | -¥2.86B | -¥3.62B |
EDINET (FSA Japan)
有価証券報告書－第16期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第15期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第14期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第13期(2022/01/01－2022/12/31)
Extracted from XBRL: 39 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.